Trifluoperazine Binding Research Articles

Effects of calmodulin antagonists on secretion of bile and bile acid.

In the isolated perfused rat liver, the effects of calmodulin (CaM) antagonists, chlorpromazine (CPZ), trifluoperazine (TFP), W-7 and W-5, on secretion of bile and bile acid were compared. Without addition of taurocholic acid to the perfusate, TFP (200 microM or higher), CPZ (200 microM) and W-7 (400 microM) decreased the bile flow transiently. In contrast, W-5 did not decrease the bile flow. Taking into consideration the binding of TFP and CPZ to bovine serum albumin in the perfusate, they diminished the bile flow by inhibiting CaM function. This was also supported by the difference between the effects of W-7 and W-5. These findings suggested that CaM was involved in the secretion of bile. Under the constant infusion of taurocholic acid into the perfusate, CaM antagonists decreased the secretion of bile acid. However this might be due to the inhibition of bile acid uptake, because these agents inhibited the uptake into isolated rat hepatocytes. The concentrations required for inhibition of the uptake were near to those which decreased the viability, suggesting that the inhibition was due to their non-specific cytotoxic effect. Future studies must be carried out to determine whether CaM is involved in the secretion of bile acid.

Binding of trifluoperazine and fluorene-containing compounds to calmodulin and adducts

Calmodulin can be specifically acylated with a fluorene-containing hydrophobic spin-labeling reagent at just Lys 75 or at Lys 75 and Lys 148. The binding of trifluoperazine to calmodulin and the two adducts was determined using a Hummel-Dreyer procedure, and binding of the phenothiazine was found to be characterized by apparent positive cooperativity and an apparent limiting stoichiometry of about seven binding sites per protein molecule. Two non-reactive fluorene-containing compounds were synthesized, and both reagents exhibited far less binding to calmodulin than did trifluoperazine. One of these was also assayed for binding to the monolabeled adduct, and this binding was about half that observed with calmodulin and was non-cooperative. Thus, the qualitative andquantitative binding parameters of hydrophobic groups to calmodulin can be quite different.

Sites of interaction of calmodulin with trifluoperazine and glucagon

The combination of glucagon with calmodulin alters the microenvironment of Tyr-99, but not Tyr-138, and is blocked by the binding of trifluoperazine by calmodulin. Trp-25 of glucagon is probably involved in the zone of interaction, which may also overlap one or more strong binding sites for trifluoperazine. From energy transfer measurements, one strong binding site for trifluoperazine probably involves the N-terminal region of binding domain III. Energy transfer and other evidence suggest that the zone of contact with glucagon involves the N-terminal region of binding domain III.

The nature of the trifluoperazine binding sites on calmodulin and troponin-C

We have employed 1H-nuclear magnetic resonance spectroscopy to study the interaction of the drug trifluoperazine with calmodulin and troponin-C. Distinct trifluoperazine-binding sites exist in the N- and C-terminal halves of both proteins. Each site consists of a group of hydrophobic side-chains brought into proximity by the Ca 2+-dependent juxtaposition of two α-helical segments of the protein, each, in turn, belonging to a different Ca 2+-binding site in the protein half. The trifluoperazine-induced inhibition of the biological activating ability of calmodulin appears to result from conformational restrictions conferred upon the protein by the bound drug.

Metal ion and drug binding to proteolytic fragments of calmodulin: proteolytic, cadmium-113, and proton nuclear magnetic resonance studies.

Tryptic fragmentation of Ca2+-saturated calmodulin (CaM) takes place mainly at Lys-77; however, proteolysis can occur instead at Arg-74 or Lys-75. This cleavage pattern results in the production of three peptides each of the amino- and carboxy-terminal halves of CaM of slightly different length. A purification scheme for the three carboxy-terminal half-peptides is reported. Proton nuclear magnetic resonance (1H NMR) studies of peptides comprising the amino- or carboxy-terminal half of CaM reveal the great structural similarity between these two proteolytic fragments and the intact protein. Since this was observed for the apoprotein as well as the Ca2+-saturated protein, this means that the two halves of the protein are independently folded. A comparison of the changes in the 1H NMR spectra observed for the intact protein and the fragments upon addition of Ca2+ clearly identified sites III and IV as the two high-affinity binding sites. Furthermore, addition of Ca2+ or Cd2+ induces qualitatively similar changes in the spectra, thus indicating that Cd2+ is a reliable replacement for Ca2+ in these studies. Subsequent 113Cd NMR studies of trifluoperazine (TFP) binding to tryptic and thrombic fragments of calmodulin revealed the presence of two distinct drug binding sites, one located in the amino-terminal half and one located in the carboxy-terminal half. The spectral changes, induced upon addition of the antipsychotic drug, were similar to those observed upon binding of TFP to intact calmodulin. The strongest TFP binding site is located in the carboxy-terminal half.

Calmodulin in starfish oocytes: II. Trypsin treatment suppresses the trifluoperazine-sensitive step

The 1-methyladenine-induced oocyte maturation in starfish is reversibly inhibited by the anticalmodulin drug, trifluoperazine (TFP). However, when oocytes are exposed for 10 min to trypsin, they lose their sensitivity to TFP. Trypsin does not alter the length of the hormone-dependent period (1-methyladenine minimal contact time) or the 1-methyladenine concentration requirements. Trypsin-treated oocytes remain sensitive to other maturation inhibitors such as procaine, theophylline, caffeine, and D-600. Trypsin exposure modifies the protein pattern composition of the oocyte cortex (breakdown of a 140-kDa protein). TFP binding site localization was studied using fluorescence microscopy: in addition to a general diffuse fluorescence, staining is localized to probably acidic granules located in the cortex. Results are discussed in relation to calmodulin and plasma membrane calmodulin-dependent enzyme involvement in the stimulation of starfish oocyte maturation.

Localization of a trifluoperazine binding site on troponin C.

Trifluoperazine (TFP) was shown to interact with the cyanogen bromide fragment 9 (CB9) (residues 84-135) of rabbit skeletal troponin C and with a synthetic peptide representing the N-terminal region of CB9. The phenothiazine did not affect the calcium binding property of CB9 as observed by proton magnetic resonance and circular dichroism spectroscopies. The calculated calcium binding constants for CB9 in the presence and absence of trifluoperazine were identical (KCa2+ = 1.3 X 10(5) M-1). Localization of the trifluoperazine binding site was achieved by analyzing the 1H NMR spectrum of CB9 and of a synthetic fragment corresponding to residues 90-104 of CB9. Drug-induced shifting and broadening of the ring protons of phenylalanine residues and the methyl resonances of alanine, leucine, and isoleucine residues suggest that the segment 95-102 is in close proximity to the phenothiazine aromatic region. The neighboring negative side chains in the peptide sequence also suggest that the single positive charge present on the piperazine nitrogens of trifluoperazine may interact with them and sterically block a region of interaction of calmodulin (CaM) and troponin C (TnC) with modulated proteins such as phosphodiesterase. Primary sequence analysis of CaM and troponin C reveals that a homologous hydrophobic region to site 3 is also found in the N-terminal region of site 1 of both calcium binding proteins. Binding of TFP to CB9 occurs both in the presence and absence of calcium since the hydrophobic region in these small fragments is completely accessible to TFP whether calcium is present or not. The dissociation constant of the drug to apoCB9 (8 microM) was obtained by ellipticity measurements at 222 nm and was comparable to the 5 microM value obtained by Levin and Weiss [Levin, R. M., & Weiss, B. (1978) Biochim. Biophys. Acta 540, 197-204] for calcium-saturated rabbit skeletal troponin C.

Dopaminergic effects of buspirone, a novel anxiolytic agent

The novel anxiolytic drug buspirone raised striatal levels of the dopamine metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) 1 hr after oral administration. This effect was dose-dependent with a peak at 60 min. No changes were observed in the levels of 3-methyxytyramine (3MT), the extraneuronal metabolite of dopamine. Noradrenaline, serotonin and its metabolite 5-hydroxyindoleacetic acid (5HIAA) were not affected. Buspirone displaced [ 3H]spiroperidol from striatal binding sites, with an ic 50 (1.8 × 10 −7 M), comparable to that of clozapine ( ic 50 = 1.4 × 10 −7 M ) but considerably lower than that of haloperidol (4.7 × 10 −9 M). Buspirone was only a weak inhibitor of dopamine-stimulated adenyl cyclase. Buspirone was not active on the binding of trifluoperazine to calmodulin and did not modify calmodulin-induced activation of phosphodiesterase (PDE). Repeated administration of buspirone did not increase the number of DA receptors. These data show that, although buspirone has antidopaminergic activity, it can hardly be classified as a classic neuroleptic agent.

43Ca NMR studies of Ca 2+- Tetrahymena calmodulin complexes

43Ca NMR spectra of Ca 2+- Tetrahymena calmodulin( Tet. CaM.) complexes have been observed under various conditions. Off-rate of Ca 2+ from Tet. CaM. is estimated to be approx. 2.7 × 10 3 s −1 under a certain assumption. Relaxation rates of 43Ca NMR of Ca 2+- Tet. CaM. are remarkably increased(by one order in magnitude) by adding trifluoperazine(TFP), a potent calmodulin antagonist. Relaxation parameters estimated suggest that Ca 2+ mobility is reduced by the TFP binding. A stoichiometry of TFP is two moles per Tet. CaM. molecule. The relaxation rates of 43Ca NMR signals are increased by adding excessive Mg 2+ to the Ca 2+- Tet. CaM. solutions. The addition of Mg 2+ to the Ca 2+- Tet. CaM. complex decreases apparent pKa value of the complex as well.

Relationship between anti-diarrheal activity and binding to calmodulin

Several neuroleptics known to bind to calmodulin were tested for anti-diarrheal activity and were compared with the opiate anti-diarrheals loperamide and diphenoxylate. All inhibited the intestinal fluid secretion induced by 16,16-dimethyl prostaglandin E 2 and castor oil-induced diarrhea in rats as a function of dose, the order of potency being loperamide⋟diphenoxylate>chlorpromazine >promethazine>amitriptyline . The opiates loperamide and diphenoxylate were found to compete with [ 3H]trifluoperazine binding to calmodulin in the presence of calcium. These opiates were approximately 3 times more potent inhibitors of [ 3H]trifluoperazine binding than chlorpromazine. A positive correlation between calmodulin binding and anti-diarrheal activity was demonstrated.

Amyloidosis in children with familial Mediterranean fever.

The clinical and laboratory findings of 35 children with familial Mediterranean fever who developed amyloidosis are described. The types, frequency, and severity of attacks of familial Mediterranean fever in these children were no different from patients with this disease without amyloidosis. Although amyloid was widely deposited in all tissues, the major clinical manifestations of the amyloidosis were proteinuria, the nephrotic syndrome, and progressive renal failure. Only 20% of the patients were alive 5 years after the first appearance of proteinuria.

Specificity of the binding of trifluoperazine to the calcium-dependent activator of phosphodiesterase and to a series of other calcium-binding proteins

Trifluoperazine inhibits the activation of phosphodiesterase by binding to the calcium-dependent activator. To determine further the specificity by which trifluoperazine binds to activator, we compared the binding of trifluoperazine to activator prepared from several species and tissues and to a number of other calcium-binding proteins devoid of activator activity. Trifluoperazine binds to activator prepared from human, bovine, rat and rabbit brain and from chick embryo fibroblasts. In each case, the binding of trifluoperazine to activator was qualitatively similar and related quantitatively to the ability of the preparation to activate phosphodiesterase. Of the other calcium-binding proteins examined, namely, troponin-C, S-100 protein, phospholipase A, phospholipase B and myosin light chain, only troponin-C displayed any significant calcium-specific binding of trifluoperazine. The binding to troponin-C, however, appeared to be different from the binding to activator; whereas the binding of trifluoperazine to actovator showed no cooperativity, the binding to troponin-C showed positive cooperatively. These results and earlier data showing that trifluoperazine fails to bind to a variety of other proteins, indicate that the binding of trifluoperazine to the calcium-dependent activator of phosphodiesterase is selective and suggest that this binding may explain some of the biochemical and pharmacological actions of this antipsychotic agent.